Vantage Consulting Group Inc Adc Therapeutics Sa Transaction History
Vantage Consulting Group Inc
- $7.71 Million
- Q3 2024
A detailed history of Vantage Consulting Group Inc transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Vantage Consulting Group Inc holds 850,737 shares of ADCT stock, worth $1.68 Million. This represents 34.75% of its overall portfolio holdings.
Number of Shares
850,737
Previous 850,737
-0.0%
Holding current value
$1.68 Million
Previous $2.69 Million
0.33%
% of portfolio
34.75%
Previous 4.39%
Shares
4 transactions
Others Institutions Holding ADCT
# of Institutions
79Shares Held
55MCall Options Held
82.7KPut Options Held
31.5K-
Redmile Group, LLC San Francisco, CA15.7MShares$31 Million3.23% of portfolio
-
Prosight Management, LP Dallas, TX9.64MShares$19.1 Million8.15% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.53MShares$8.98 Million0.34% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$7.04 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.04MShares$6.02 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $154M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...